Executive Education, Value Creation in Private Equity and Venture Capital
(2016 - 2016)
(2009 - 2009)
(2007 - 2008)
2021
Apollo Health Ventures is an Early Stage Investment Firm interested in accelerating breakthrough scientific discoveries to the clinic by building life science companies around new therapeutic technologies. Apollo Health Ventures focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as Dementia, Heart Disease and Cancer, with the ultimate goal of increasing healthy human lifespan. Apollo invests in early stage companies, works with scientists and entrepreneurs to create new ventures, and engages in hypothesis-driven company building.
2022
Booster is developing first-in-class proteasome enhancers to treat multiple diseases.
2023
Haya is dedicated to developing advanced RNA-targeted therapies, particularly focusing on long non-coding RNAs, to treat fibrotic diseases at their core.
2022
Auron is shifting the paradigm of cancer treatment to target key drivers of dysregulated differentiation and cellular plasticity, leveraging a machine learning, multi-omics based platform.
2022
2022
Cleara progresses a pipeline of compounds that are capable of selectively eliminating senescent and senescent-like cancer cells.
2018 - 2021
2018 - 2021
Since 1998, Wellington Partners has been a leading European Venture Capital firm investing in early- and growth-stage Life Science companies. Led Wellington's investments in - Confo Therapeutics - Imcheck Therapeutics www.wellington-partners.com
2019 - 2021
2019 - 2021
Confo utilizes pioneering G protein-coupled receptor (GPCR) technology to build up a portfolio of first-in-class programs addressing difficult-to-drug disease targets in neurology and beyond. The company entered a global licensing agreement with Eli Lilly valued at 630 million USD.
2019 - 2021
2019 - 2021
UroMems is developing an electrical artificial urinary sphincter (eAUS) system for treatment of medium to severe stress urinary incontinence.
2019 - 2021
2019 - 2021
SNIPR BIOME develops CRISPR-based drug candidates for infections and microbiome engineering in auto-immune and malignant disorders.
2017 - 2018
2017 - 2018
Cardior is focused on the development and clinical validation of noncoding (ncRNA) RNA therapeutics for patients with myocardial infarction and heart failure. Novo Nordisk acquired Cardior for up to €1.025 Bn.